Loading...
•
Dec 31, 2020
SpringWorks Therapeutics Q4 2020 Earnings Report
SpringWorks Therapeutics' Q4 2020 financial results were reported, highlighted by revenue from the Jazz Pharmaceuticals agreement and advancements in clinical trials.
Key Takeaways
SpringWorks Therapeutics reported Q4 2020 financial results, featuring $35.0 million in revenue from the Jazz Pharmaceuticals agreement. The company's R&D expenses were $15.3 million, and G&A expenses totaled $8.5 million. Net income for the quarter was $11.3 million, and cash, cash equivalents, and marketable securities amounted to $561.8 million.
Revenue for Q4 2020 was $35.0 million, driven by the upfront payment from Jazz Pharmaceuticals.
R&D expenses increased to $15.3 million due to growing employee costs and clinical trial expenses.
G&A expenses rose to $8.5 million, reflecting increased personnel and business activities.
The company ended 2020 with a strong cash position of $561.8 million, including proceeds from a public offering and the Jazz Pharmaceuticals payment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...